

[ Meet the Professor ]

## **13th Meet The Professor Advanced International Breast Cancer Course (AIBCC)**

Padua, September 21-23, 2017

The Conference will include:

### **1) Lectures:**

Internationally recognized speakers provide a balanced overview of selected topics

### **2) Clinical Case Discussions:**

Difficult or controversial cases related to the diagnostic or therapeutic management of early and advanced breast cancer will be presented. All participants will be requested to select their vote among a predefined list of options.

Expert panelists will then provide their opinion and discuss the audience's choices.

### **3) Highlights:**

Internationally recognized speakers give an update of significant advances presented at major meetings (ASCO, ESMO, SABCS, ST. GALLEN) on preselected topics

**[Preliminary Program]**

**Thursday, September 21<sup>st</sup>**

8.00 Registration

9.15 Introduction to the Conference  
Pierfranco Conte, Gabriel N. Hortobagyi

**SESSION I-LIFE STYLE AND BREAST CANCER**

Chairmen: Gabriel N. Hortobagyi, Stefania Migliuolo

9.30 Body Mass Index: role as risk factor and predictor of endocrine therapy efficacy  
Andrea De Censi

10.00 Hormone replacement therapy: the good and the bad  
Marco Gambacciani

10.30 Breast cancer and pregnancy  
Fedro Peccatori

11.00 Q&A

11.15 *Coffee break*

**SESSION II- HIGH RISK WOMEN AND PERSONALISED SCREENING**

Chairmen: Andrea De Censi

11.45 Identification of high risk women: from family history to multigene panels  
Marco Montagna

12.15 Personalized screening (including women with dense breasts or breast implants/augmentation)  
Enrica Baldan

12.45 Q&A

13.00 *Lunch*

14.00 **Multidisciplinary Tumor Board 1 – Management of women at high risk of breast cancer**

Chairmen: Gabriel H. Hortobagyi, Luigi Pescarini

Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.

Participants: Enrica Baldan, Andrea De Censi, Marco Gambacciani, Sibylle Loibl, Stefania Migliuolo, Marco Montagna, Stefania Montemezzi, Enrico Orvieto, Fedro Peccatori, Massimo Rugge

**SESSION III-SURGERY & RADIOTHERAPY**

Chairmen: Jacek Jassem, Elefterios Mamounas

- 15.00 Management of in situ carcinoma: state of art  
tbd
- 15.30 Sentinel node biopsy: when should be spared?  
Oreste Gentilini
- 15.50 Sentinel node biopsy: before or after NACT?  
Elefterios Mamounas
- 16.10 Lipofilling: are preclinical data fully reassuring?  
Francesco Bertolini
- 16.30 Lipofilling after breast cancer: the surgeon's point of view  
tbd
- 16.50 Radiation therapy: when more is better and when less is good  
Philip Poortmans
- 17.20 Q&A
- 17.30 **Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2017**
- 18.00 Lecture of the Awardee
- 18.30 *Cocktail*
- 20.00 Adjourn

**Friday, September 22<sup>nd</sup>**

**SESSION IV – PATHOLOGY, GENOMICS & MOLECULAR BIOLOGY**

Chairmen: Aleix Prat, Massimo Rugge

- 9.00 Baseline assessment: new AJCC classification  
Gabriel N. Hortobagyi
- 9.30 HER2 testing guidelines for the clinicians: equivocal means yes or no?  
Giuseppe Viale
- 10.00 Genomic tests: clinical utility after TailoRx and Mindact  
Maria Vittoria Dieci
- 10.30 Liquid biopsy (ctDNA, CTC, miRNA): ready for clinical use?  
Leticia de Mattos-Arruda
- 11.00 Q&A
- 11.15 *Coffee Break*

**SESSION V – ACTIONABLE PATHWAYS IN BREAST CANCER SUBTYPES**

**Chairmen:** Pierfranco Conte, Sibylle Loibl

11.45 Luminal tumors and endocrine resistance  
Stephen Johnston

12.15 Targeting the immune system: TN and beyond  
Peter Schmid

12.45 HER2+ and trastuzumab resistance  
Aleix Prat

13.15 Q&A

13.30 *Lunch*

14.30 **Multidisciplinary Tumor Board 2 – Challenging cases for pathologists and clinicians (including CUP syndrome, breast cancer during pregnancy)**

Chairmen: Fernando Bozza, Pierfranco Conte

Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.

Participants: Hesham A. Gaballah Elghazaly Gabriel N Hortobagyi, Jacek Jassem, Stephen Johnston, Sibylle Loibl, Elefterios Mamounas, Miguel Martin, Stefania Migliuolo, Fedro Peccatori, Philip Poortmans, Aleix Prat, Massimo Rugge, Giuseppe Viale

16.00 *Coffee break*

**SESSION VI – ADJUVANT TREATMENTS**

Chairmen: Gabriel N. Hortobagyi, Stephen Johnston

16.20 HR+ disease: when more is better – Michael Gnant  
: when less is good – Giuseppe Curigliano

17.00 HER2+ disease: when more is better - Javier Cortes Castan  
: when less is good – Pier Franco Conte

17.40 Triple Negative: when more is better- Valentina Guarneri  
: when less is good – Miguel Martin

18.20 Q&A

18.30 Adjourn

**Saturday, September 23<sup>rd</sup>**

**SESSION VIII – ABC PATIENTS**

Chairmen: Hesham A. Gaballah Elghazaly, Valentina Guarneri

9.00 New therapeutic algorithms

HR+ ABC - Stephen Johnston

HER2+ ABC - Sibylle Loibl

TN ABC – Hope Rugo

10.30 Q&A

10.45 Highlights from major meeting (ASCO, ESMO, SABCS, ST GALLEN)

Jassem Jacek

11.15 *Coffee break*

11.45 **Multidisciplinary Tumor Board 3 – Management of Advanced Breast Cancer**

Chairmen: Pierfranco Conte, Miguel Martin

Fellows will present case histories, will ask questions to the audience and the participants will vote their preferred choices. A panel of experts including oncogenetists, radiologists, surgeons, oncologists and representatives of advocacy group will comment the votes and express their opinions.

Participants: Pier Franco Conte, Giuseppe Curigliano, Hesham A. Gaballah Elghazaly, Valentina Guarneri, Jacek Jassem, Gabriel n. Hortobagyi, Stephen Johnston, Sibylle Loibl, Miguel Martin, Stefania Migliuolo, Fedro A. Peccatori, Phili Poortmans, Aleix Prat, Hope Rugo

13.15 Adjourn and final evaluation questionnaire

**[Aims]**

Breast cancer represents the front runner in cancer research in many aspects. First, this is a common, chronic and lethal disease where medical interventions are successfully inducing a continuous decline in mortality in spite of increasing incidence. Second, biology drives the entire diagnostic-therapeutic work up of these patients. This is why, nowadays, a breast multidisciplinary team should also include pathologists, molecular biologists, oncogeneticists besides the "classic" clinical specialties. Third, many highly effective interventions are available for each step of the diagnostic and therapeutic work-up of these patients. The increased complexity of the disease, the availability of multiple effective choices and the high expectations of our patients are raising the bar of clinical excellence in this field.

With this goal in mind, the Programme of this international Conference includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.

Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.

This 13<sup>th</sup> Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where international opinion leaders and attendees will exchange experiences and share the most exiting advances.

In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 13<sup>th</sup> AIBCC will award the 7<sup>th</sup> International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year.

We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.

**[Addressed to]**

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists and nurses.

**[ Directors ]**

Pierfranco Conte  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padua (I)

Gabriel N. Hortobagyi  
Department of Breast Medical Oncology  
The University of Texas - MD Anderson Cancer Center  
Houston (USA)

**[Scientific Committee]**

Hesham Ahmed Gaballah Elghazaly  
Department of Clinical Oncology and nuclear medicine  
University of Ainshams  
Cairo (EG)

Valentina Guarneri  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padua (I)

Jacek Jassem  
Department of Oncology and Radiotherapy  
Medical University of Gdansk (PL)

Stephen Johnston  
NIHR Biomedical Research Centre for Cancer  
Royal Marsden NHS Foundation Trust & Institute of Cancer Research  
London (UK)

Sibylle Loibl  
German Breast Group  
Department of Medicine and Research  
University of Frankfurt (D)

Miguel Martin  
Medical Oncology Service  
Hospital Universitario Gregorio Marañon  
Madrid (S)

Stefania Migliuolo  
Europa Donna Italia  
Milan (I)

Fedro Alessandro Peccatori  
Department of Medical Oncology  
European Institute of Oncology (IEO)  
Milan (I)

Philip Poortmans  
President of ESTRO; President-Elect of ECCO  
Department of Radiation Oncology  
Institut Curie  
Paris (F)

Aleix Prat  
Institute of Oncology (VHIO)  
Vall d'Hebron- Institute of Oncology  
Barcellona (E)

**[Speakers]**

Enrica Baldan  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padua (I)

Francesco Bertolini  
Department of Emato-Oncology  
European Institute of Oncology  
University of Milan (I)

Fernando Bozza  
Division of Breast Surgery  
Istituto Oncologico Veneto IRCCS  
Padua (I)

Javier Cortes Castan  
Institute of Oncology  
Vall d'Hebron (VHIO)  
Barcellona (S)

Giuseppe Curigliano  
Department of Oncology  
European Institute of Oncology  
University of Milan (I)

Andrea De Censi  
Medica and Preventive Oncology  
E.O. Galliera Hospital  
Genoa (I)

Leticia De Mattos-Arruda  
Institute of Oncology  
Vall d'Hebron (VHIO)  
Barcelona (S)

Maria Vittoria Dieci  
Division of Medical Oncology 2  
Istituto Oncologico Veneto IRCCS  
Department of Surgery, Oncology and Gastroenterology  
University of Padua (I)

Marco Gambacciani  
Obstetrics & Gynecology Unit  
S. Chiara Hospital  
Pisa (I)

Oreste Gentilini  
Breast Unit  
S. Raffaele Hospital  
Milan (I)

Michael Gnant  
Department of Surgery  
Medical University  
Wien (A)

Eleuterios Mamounas  
Comprehensive Breast Program  
MD Anderson Cancer Center  
Orlando (USA)

Marco Montagna  
Hereditary Tumors Group Breast and Ovary Cancer  
Department of Oncological Molecular Diagnostic and Immunology  
Istituto Oncologico Veneto  
University of Padua (I)

Stefania Montemezzi  
Department of Radiology  
University Hospital  
Verona (I)

Enrico Orvieto  
General Pathology and Cytopathology Unit  
Department of Medicine-DIMED  
University of Padua (I)

Luigi Pescarini  
Department of Radiology  
Diagnostic Breast Unit  
Istituto Oncologico Veneto IRCCS  
University of Padua (I)

Massimo Ruge  
General Pathology & Cytopathology Unit  
Department of Medicine-DIMED



University of Padua (I)

Hope Rugo  
Breast Oncology Clinical Trials Program  
UCSF Carol Franc Buck Breast Care Center  
San Francisco (USA)

Peter Schmid  
Centre for Experimental Cancer Medicine  
Bart Cancer Institute  
Queen Mary University  
London (UK)

Giuseppe Viale  
Department of Pathology  
European Institute of Oncology  
University of Milan (I)

[ **Meeting Venue** ]

Palazzo del Bo  
Via VIII Febbraio, 2  
Padua (I)